Literature DB >> 10091771

Telomerase activity in patients with transitional cell carcinoma: a preliminary study.

M A Rahat1, N Lahat, H Gazawi, M B Resnick, Y Sova, G Ben-Ari, M Cohen, A Stein.   

Abstract

BACKGROUND: Telomerase activity is not detectable in normal cells, and their telomers shorten until the chromosome is unable to replicate. Immortal cells have short but stable chromosomes and increased telomerase activity. Transitional cell carcinoma (TCC) has only a few useful markers of diagnostic or prognostic importance. The objective of this study was to determine whether there was a correlation between telomerase activity and the grade or stage of TCC, and whether the enzyme's activity could serve as a biochemical marker of this tumor.
METHODS: The study included 29 patients with TCC. From each patient, samples of urine cells were obtained, and a cup biopsy was taken from an apparently normal area as well as from a part of the bladder tumor resected transurethrally. Control uroepithelial biopsies were taken from normal transitional cell sites from non-TCC patients. Biopsies or cells were subjected to either histologic examination or telomerase activity determination.
RESULTS: Twenty-six of 29 (90%) of the tumor biopsies exhibited telomerase activity. Most of the cup biopsies were categorized as metaplastic or dysplastic, and 20 of 29 (69%) of these exhibited telomerase activity. Telomerase activity was found in 17 of 21 (81%) of the urine cells but in only 3 of 14 (21%) of control urine cells. All (10 of 10) of the uroepithelial biopsies taken from non-TCC patients did not show any telomerase activity.
CONCLUSIONS: In this study, almost all tumor biopsies exhibited telomerase activity. The high incidence of telomerase activity found in cup biopsies of the malignant field uroepithelial cells from cup biopsies of TCC patients may suggest that telomerase could be activated early in carcinogenesis. A high incidence of telomerase activity was found in voided uroepithelial cells of TCC patients; however, no correlation between this activity and the histologic determination of grading and staging of the tumor was found.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10091771

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

Review 1.  Early bladder cancer: concept, diagnosis, and management.

Authors:  Hiroshi Kitamura; Taiji Tsukamoto
Journal:  Int J Clin Oncol       Date:  2006-02       Impact factor: 3.402

2.  Thyroid autoantibodies, telomerase activity, vascular endothelial growth factor, and bone scanning.

Authors:  A van Ophoven; B Patel; M K Rauch; A Belldegrun
Journal:  Rev Urol       Date:  1999

3.  Telomerase activity detected by quantitative assay in bladder carcinoma and exfoliated cells in urine.

Authors:  R Fedriga; R Gunelli; O Nanni; F Bacci; D Amadori; D Calistri
Journal:  Neoplasia       Date:  2001 Sep-Oct       Impact factor: 5.715

4.  Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma.

Authors:  D Chao; S J Freedland; A J Pantuck; A Zisman; A S Belldegrun
Journal:  Rev Urol       Date:  2001

5.  Comparison of human telomerase reverse transcriptase messenger RNA and telomerase activity as urine markers for diagnosis of bladder carcinoma.

Authors:  H Bialkowska-Hobrzanska; L Bowles; B Bukala; M G Joseph; R Fletcher; H Razvi
Journal:  Mol Diagn       Date:  2000-12

Review 6.  Alternatives to cytology in the management of non-muscle invasive bladder cancer.

Authors:  Gilad E Amiel; Tung Shu; Seth P Lerner
Journal:  Curr Treat Options Oncol       Date:  2004-10

7.  Telomerase is upregulated in irreversible preneoplastic lesions during bladder carcinogenesis in rats.

Authors:  Toru Shimazui; Yoshihiro Ami; Naoto Miyanaga; Yukitaka Ideyama; Takahito Nakahara; Hideyuki Akaza
Journal:  Jpn J Cancer Res       Date:  2002-05

8.  Telomere instability in papillary bladder urothelial carcinomas: Comparison with grading and risk of recurrence.

Authors:  Giuseppe Mucciardi; Alessandro Gali'; Valeria Barresi; Massimo Mucciardi; M'Hammemd Aguennouz; Antonino Inferrera; Carlo Magno
Journal:  Indian J Urol       Date:  2014-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.